Optimal use of biologics in the management of Crohn's disease

Research output: Contribution to journalReview articlepeer-review

Abstract

Crohn's disease (CD) is a chronic relapsing and remitting disorder of the gastrointestinal tract with no known cure. The inflammation that drives the disease can lead to debilitating symptoms and a number of complications that may lead to surgery. The introduction of biologic therapy a decade ago has offered a new option for patients failing conventional therapy. Over time, biologic therapy has also led to the desire to achieve treatment goals beyond the control of symptoms. In order to achieve short-term and long-term goals with these new agents, it is important to review how these therapies may be optimized for the best results.

Original languageEnglish
Pages (from-to)179-189
Number of pages11
JournalTherapeutic Advances in Gastroenterology
Volume3
Issue number3
DOIs
Publication statusPublished - May 2010
Externally publishedYes

Keywords

  • Adalimumab
  • Biologic therapy
  • Certolizumab
  • Crohn's disease
  • Infliximab
  • Natalizumab
  • Prognostic factors

Fingerprint

Dive into the research topics of 'Optimal use of biologics in the management of Crohn's disease'. Together they form a unique fingerprint.

Cite this